Mirum Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 675.25, 815.2, 1063.92, 1367.45, 1725.44 ], "ebit_estimate": [ -909.91, -26.78, 152.75, 427.44, 730.89 ], "ebitda_estimate": [ -905.91, -39.43, 146.24, null, null ], "net_income_estimate": [ -915.41, -12.97, 168.26, 423.6, 699.06 ], "per_share_eps_estimate": [ -15.61, -0.9, 2.16, 4.63, 8.75 ], "eps_nri_estimate": [ -15.65, -0.67, 2.59, 5.42, 8.75 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.22, 2.79, 7.03, null, null ], "pretax_income_estimate": [ -917.22, -29.27, 181.37, 458.32, 758.71 ], "operating_cash_flow_per_share_estimate": [ -3.55, 1.42, 3.99, null, null ], "roa_estimate": [ -91, -3.3, 15.5, null, null ], "roe_estimate": [ -540.77, 73.22, 53.11, null, null ], "gross_margin_estimate": [ 85.95, 86.15, 91, 92, 92 ], "operating_cash_flow_estimate": [ -208.92, 83.57, 234.82, null, null ], "pettm_estimate": [ 0, 0, 56.49, 26.41, 13.96 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "26.22", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 26.22, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 3.67, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 166.12, 172.02, 177.43, 181.73, 190.54, 203.43, 217.33 ], "ebit_estimate": [ -33.2, -26.39, -30.66, -19.18, -19.48, -18.16, -17.01 ], "ebitda_estimate": [ -8.74, -13.58, -26.14, null, null, null, null ], "net_income_estimate": [ -37.9, -34.46, -31.66, -21.94, -22.87, -17.58, -13.69 ], "per_share_eps_estimate": [ -0.71, -0.64, -0.72, -0.43, -0.36, -0.22, -0.05 ], "eps_nri_estimate": [ -0.68, -0.6, -0.76, -0.42, -0.35, -0.2, -0.02 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -38.69, -34.96, -32.63, -25.03, -25.41, -19.82, -15.52 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -104.18, -334.14, -238.2, null, null, null, null ], "gross_margin_estimate": [ 90, 90, 90, 90, 90, 90, 90 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "26.22", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 26.22, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 3.67, "future_operating_cash_flow_per_share_estimate_growth": null }